Australia's second-largest fertility services provider has downgraded its full-year earnings outlook, due to fewer would-be parents seeking its help.
Monash IVF, which has an assisted reproduction market share of about 20 per cent, now expects to report an underlying net profit between $17 million and $18 million for the 2025/26 financial year.
"The key driver for the revised FY26 earnings outlook is lower than expected Australian ART (assisted reproductive technology) market activity in the second half," it told the stock exchange on Friday.
It had previously expected a result of around $20 million.
Australian stimulated cycle volumes are down 4.7 per cent in the three months to April, from the same period last year, according to Medicare data cited by the company.
